Cargando…
A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes
BACKGROUND: Cancers produce soluble and cell-associated molecules that can suppress or alter antitumor immunity. Preclinical studies suggest the disease burden may alter the cytokine profile of helper T cell responses to cancer antigens. We studied cytokine production by helper T cells responding to...
Autores principales: | Dillon, Patrick M, Olson, Walter C, Czarkowski, Andrea, Petroni, Gina R, Smolkin, Mark, Grosh, William W, Chianese-Bullock, Kimberly A, Deacon, Donna H, Slingluff, Craig L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131803/ https://www.ncbi.nlm.nih.gov/pubmed/25126421 http://dx.doi.org/10.1186/2051-1426-2-23 |
Ejemplares similares
-
A multi-epitope melanoma helper peptide vaccine durably increases Th1 cytokine production by responding lymphocytes
por: Dillon, Patrick M, et al.
Publicado: (2013) -
Immunologic hierarchy and promiscuity of melanoma helper peptides
por: Hu, Yinin, et al.
Publicado: (2013) -
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021) -
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)
por: Slingluff, Jr., Craig L, et al.
Publicado: (2021) -
A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)